The effect ofhyaluronidase and a combination of hyaluronidase with Adriamycin was investigated on several breast cancer models in vitro and in vivo. In vitro enzyme treatment (using concentrations up to 80 000 IU/ 1) of routine (MXT-, MXT -+, and MXT +) and human (MCF-7, ZR-75-1 and T-47-D) breast cancer cell lines did not inhibit tumour cell proliferation (measured by a kinetic crystal violet assay) in either case. Although highdose hyaluronidase (1.2 x 106 IU/kg) was ineffective, when administered peritumourally to the MXT M3.2 mammary carcinoma of the B6D2F 1 mouse, it is remarkable that five "megadoses" were excellently tolerated. However, the antineoplastic activity of Adriamycin against the oestrogen-receptor-positive variant of the MXT tumour was significantly enhanced by combination with concentrations of hyaluronidase that were inactive per se, both in vitro and in vivo. Interestingly, the enhancement of the in vivo antitumour activity was not compromised by toxic side-effects.
Introduction
Whereas numerous studies have confirmed the diagnostic value of elevated serum levels of hyaluronic acid associated with malignant mesothelioma (Frebourg et al. 1987; Pettersson et al. 1988; Dahl et al. 1989) and Wilms' nephroblastoma (Wu et al. 1984; Stern et al. 1991) , there have been few reports of raised serum levels in other types of advanced cancer (Delpech et al. 1985; Dahl and Laurant 1988) . Cooper and Forbes (1988) presented data on the distribution of serum hyaluronic acid in patients with * Dedicated to Professor Wolfgang Wiegrebe on the occasion of his 60th birthday Correspondence to: G. Bernhardt metastatic cancer or large local tumours (myeloma, melanoma, sarcoma, cancer of the pancreas, stomach, colon, lung -small cell and non-small cell, prostate, ovary and breast). Within each type of cancer individual patients showed strongly elevated levels of hyaluronic acid, but statistically significant, overall increased levels were only present in pancreatic cancer, small-cell lung cancer and carcinoma of the prostate.
Although increased synthesis of glycosaminoglycans is not a universal characteristic of tumours, it seems likely that hyaluronic acid production plays an important role in tumour cell proliferation, differentiation, invasion and metastasis (Knudson et al. 1989) . In this context, hyaluronan has been implicated in the pathology of experimental and human breast cancer (Angello et al. 1982; Kimata et al. 1983; Marotta et al. 1985; Knudson et al. 1989; Decker et al. 1989; Prehm 1990) .
Therefore, it is conceivable that breast cancer might be an indication for the therapeutic application of hyaluronidase, an enzyme cleaving hyaluronic acid. Hyaluronidase has for some time been used as an additive to chemotherapy in several studies (Baumgartner 1988 ) including a phase I trial (Baumgartner et al. 1988) .
The pharmacology of hyaluronidase and its potential role in the treatment of malignant disease has been reviewed recently (Baumgartner 1987; Baumgartner and Moritz 1988) . Although the clinical trials have shown encouraging but not definite indications of possible augmentation of the antitumour activity of the chemotherapeutics used after preinfusion of hyaluronidase0 to date most of the evidence is "pilot" in nature.
In addition, preclinical data obtained in cell culture (Liu et al. 1987; Kohno et al. 1988; Scheithauer et al. 1988; Lehnert et al. 1989 ) and experimental rodent tumour models (Seipelt and Kohlheb 1967; Pawlowski et al. 1979; Sargent et al. 1983 ) are scanty and inconsistent.
As a first approach to characterize the potential efficacy of hyaluronidase in the therapy of breast cancer, we systematically assayed the in vitro chemosensitivity of various murine (MXT-, MXT § MXT -+) and human 592 (MCF-7, T-47-D, ZR-75-1) breast cancer cell lines against increasing concentrations of hyaluronidase. As an extension of these experiments, the antitumour activity of hyaluronidase was tested in vivo, using the syngenic MXT M3.2 mammary carcinoma of the B6D2F1 mouse. Further studies using the same model clearly demonstrated that hyaluronidase combined with Adriamycin significantly enhanced the antineoplastic effect of the anthracycline, both in vitro and in vivo.
Materials and methods
Chemicals. Reagents (A-grade purity) were obtained from Merck (Darmstadt, FRG) . N-Hexamethylpararosaniline (crystal violet) was purchased from Serva (Heidelberg, FRG). All culture media were from Sigma (Miinchen, FRG), and fetal calf serum (FCS) was from Gibco (Eggenheim, FRG). Millipore-filtered water was used throughout.
Cell lines and routine culture conditions. The routine cell lines used in the in vitro studies were established from different variants of the MXT mammary carcinoma of the B6D2F1 mouse (Beckenlehner 1991) . The human breast cancer cell lines (MCF-7, T-47-D and ZR-75-1) were obtained from the American Type Culture Collection (Rockeville, Md., USA). Cell line banking and quality control were performed according to the "seed stock concept" reviewed by Hay (1988) .
Proliferation kinetics, karyology, and hormone receptor content of the human breast cancer cell lines used in our laboratory have been described elsewhere .
MCF-7 ceils were grown in Eagle's minimum essential medium containing L-glutamine, 2.2 g/1 NaHCOz, 110 mg/l sodium pyruvate (Sigma, Miinchen, FRG), and 10% .FCS. T-47-D was cultivated in RPMI-1640 medium containing L-glutamine, 2.0g/1 NaHCO3 and 10% FCS. The culture medium was supplemented with 10 mg/l bovine insulin (Sigma, Miinchen, FRG). The ZR-75-1 cell line was maintained in RPMI-1640 medium with L-glutamine, 2.0 g/1 NaHCO3, 10% FCS and 11.6 mg/1 tylosin.
The hormone-independent MXT-and MXT -+ sublines were oestrogen-receptor-negative. Cells were maintained in RPMI-1640 medium containing an additional 0.6 g/1 L-glutamine (i.e. 0.9 g/l), 2.0 g/1NaHHCO3 and 10% FCS.
The hormone-sensitive and oestrogen-receptor-positive MXT + variant required 100 ng/1 oestradiol (Sigma, Mfinchen, FRG) supplementation of the same basic medium formulation. All culture media contained 50 mg/l gentamycin (Sebio, Walchsing, FRG).
The cells were serially passaged following trypsinization using trypsin (0.05%)/EDTA (0.02%) (Boehringer, Mannheim, FRG) and cultured in a water-saturated atmosphere of 95% air and 5% carbon dioxide at 37 ~ C in 75-cm z culture flasks (Costar, Tecnomara, Fernwald, FRG).
Drugs. Hyaluronidase from bovine testis was kindly provided in highly purified, lyophilized form as Neopermease in vials containing 200000 IU (specific activity approx. 50000 IU/mg protein) with carrier gelatin (25 rag) by Sanabo Gesellschaff m.b.H, (Vienna, Austria). The enzyme was dissolved in an appropriate volume of deionized water immediately before use.
Adriamycin (doxorubicin hydrochloride) was purchased from Sigma (Mfinchen, FRG). For the in vitro chemosensitivity assay the drug was dissolved in 70% (v/v) ethanol; for in vivo testing a solution in 0.9% NaC1 was used.
Chemosensitivity assay. A standardized kinetic microassay based on crystal violet staining was used. The technical details of the procedure and the method of evaluating drug action have been discussed recently ). In brief: cells were seeded (100 lal/well) in 96-well flat-bottomed microtitration plates (Costar, Tecnomara, Fernwald, FRG) at an appropriate density of about 15 cells/microscopic field (magnification 320 x ). After 4248 h (ZR-75-1:72 h) the culture medium was removed by suction and replaced by medium (200 Ixl/well) containing drug or pure vehicle (gelatin carrier dissolved in water; Adriamycin in 70% ethanol). Drugs were added as a 1000-fold concentrated stock solution. On every plate two rows (n = 16) served as controls and two rows (n = 16) were used per drug concentration. After various times of incubation the cells were fixed with glutaraldehyde and stored in the refrigerator. At the end of the experiment all plates were stained with crystal violet simultaneously. Absorbance was measured at 578 nm using a Biotek 309 Autoreader (Tecnomara, Fernwald, FRG) . Processing procedure, data analysis and evaluation were performed as described (Reile et al. 1990; Bernhardt et al. 1992) . Results are presented as plots of absorbance or corrected T/C values versus time of incubation according to T/C .... (%) = 100 x (T-Co)/(C-Co), where T is the absorbance of the treated cells, C the absorbance of the controls, and Co the absorbance of the cells at the time when drug was added (t=0).
In vivo testing on the MXT M3.2 mammary carcinoma. Animals were housed in Macrolon cages (size III, Ehret, Memmingen, FRG) at an ambient temperature of 21 ~ C with a 12-h light/dark cycle. Mice were fed with laboratory animal chow (H-1003, Alma, Kempten, FRG) and water was provided ad libitum. The ovary-dependent MXT M3.2 tumour was propagated by s.c. implantation of about 2-mm 3 turnout pieces into the right thoracal mammary fat pad of intact 8-week-old female B6D2F1 mice (Charles River Wiga, Sulzfeld, FRG). The detailed testing procedure and the characteristics of this tumour model have been described elsewhere (SpruB et al. 1991 (SpruB et al. , 1992 . Briefly, tumours were implanted subcutaneously into the right flank of intact females on day 0, and the animals were randomly assigned to groups of ten.
In the monotherapy experiment treatment was started on day 5 by injecting 1.2 x 10 6 IU/kg hyaluronidase and vehicle (gelatin carrier) s.c. into the right flank, near to the site of transplantation.
In the combination therapy experiment hyaluronidase (1.2x 106 IU/kg, weekly) was administered peritumourally, 4h prior to the i.p. injection of Adriamycin (0.2 mg/kg, three times a week). For positive control, one group was ovariectomised 1 day after tumour transplantation (day 1).
Tumour diameters were measured with a caliper. Tumour areas were calculated as the product of two perpendicular diameters, one measured across the greatest width of the tumour.
Statistics. Significance levels of the in vitro data were calculated according to the tn~-test . The significance levels of the median tumour areas after combination therapy (in vivo experiment) were determined according to the Mann-Whitney U-test (Sokal and Rohlf 1987 b) .
Results

Effect of hyaluronidase on the cell proliferation of breast cancer cells in vitro
Increasing concentrations of hyaluronidase were tested on various murine and human breast cancer cell lines. Monotherapy with 2500, 5000, and 10 000 IU/1 hyaluronidase had no effect on the growth kinetics of the murine MXT +-mammary carcinoma. In accordance with this observation, 10000 IU/1 enzyme did not affect cell proliferation of the MXT-variant. Increasing doses of hyaluronidase (10 000, 20 000, 30 000, 40 000, and 50 000 IU/1) were not inhibitory to the oestrogen-receptor-positive MXT + subline. Further dosage escalation up to 80 000 IU/1 was ineffective against the human hormonesensitive MCF-7, ZR-75-1, and T-47-D cell lines.
High-dose hyaluronidase treatment of the MXT M3.2 mammary carcinoma of the B6D2F1 mouse
Tumour-bearing animals were treated with 1.2 x 106 IU/ kg hyaluronidase beginning on day 5 after tumour transplantation. The enzyme was injected s.c. near to the site of turnout implantation. Figure 1 shows that administration of five single doses (on days 5, 12, 19, 26, and 33) did not inhibit tumour growth, whereas typical suppression of turnout proliferation by ovariectomy was observed in this highly reproducible, ovary-dependent breast cancer model. There was no difference in tumour growth when gelatin carrier was used instead of the usual NaC1 control (Sprul3 et al. 1991 ). The five "megadoses" of hyaluronidase were very well tolerated, as indicated by the weight gain of the animals during the course of the experiment (Fig. 1, inset) . At the end of the experiment, no signs of toxic side-effects caused by hyaluronidase treatment could be detected by routine dissection of the animals.
Combination therapy with high-dose hyaluronidase and Adriamycin
In vitro testing on MXT + breast cancer cells. The effects of Adriamycin monotherapy (50 nM) and combination therapy (50 nM Adriamycin with 50 000 IU/1 hyaluronidase) on cell proliferation using the kinetic crystal violet chemosensitivity assay were compared. The results of this experiment are summarized in Fig. 2 . A slight, but significant (P=0.03) increase in the antitumour activity of Adriamycin by the addition of a concentration of hyaluronidase inactive per se was observed.
In vivo enhancement of Adriamycin activity by combination with high-dose hyaluronidase
As an extension of the in vitro combination therapy experiments, the corresponding ovary-dependent MXT M3.2 mammary tumour model of the B6D2F1 mouse was used. Drug treatment started on day 19 after tumour transplantation, whereas the positive control group was ovariectomized on day 1. Hyaluronidase (1.2 x 106 IU/kg) was injected peritumourally 4 h prior to the i.p. injection of nontoxic doses of Adriamycin (0.2 mg/kg) on days 19, 26, 33, and 40. From day 19, Adriamycin was administered three times a week. Tumour growth was only slightly delayed by Adriamycin monotherapy, whereas ovariectomy was highly effective (Fig. 3) . Interestingly, there was a dramatic augmentation of Adriamycin activity by hyaluronidase pretreatment (P<0.05) (Fig. 3) , despite the relatively late beginning of treatment. As demonstrated above (cf. Fig. 1 ), monotherapy with hyaluronidase was ineffective at the same concentration. Remarkably, the toxicity of Adriamycin was not enhanced by hyaluronidase pretreatment (cf. Fig. 3, inset) . . Inset: change of mean body weight during the course of treatment, e, Gelatin carrier control; LX, Adriamycin monotherapy; n, combination therapy with hyaluronidase and Adriamycin; o, ovariectomy control. At the end of the experiment the observed difference in median tumour area after Adriamycin monotherapy and combination therapy was significant at the P < 0.05 level (U-test) though frequently in very small amounts. When added to cultured cells, hyaluronate can influence mitosis, cell differentiation and proliferation in a complex way. Hyaluronic acid is considered to inhibit differentiation and to promote cell proliferation instead (Decker et al. 1989 ). Prehm (1990) discussed the observation that high-molecular-mass hyaluronate inhibits cell growth, whereas small fragments are stimulatory. In addition, it is known that hyaluronidase treatment of living cells stimulates the synthesis of hyaluronic acid (Philipson et al. 1985; Larnier et al. 1989) , which might result in a feed back inhibition of cell proliferation. Our experiments using three murine and three human breast cancer cell lines clearly demonstrate that cell proliferation was not inhibited by addition of increasing concentrations (from 2500 to 80 000 IU/1) of bovine testicular hyaluronidase to the culture medium. From these data (the missing inhibition of cell proliferation) there was no evidence for a direct dose-dependent effect of hyaluronidase on cell-surface constituents such as has been speculated by Scheithauer et al. (1988) However, there seemed to be a slight tendency towards growth stimulation of the MXT § and the T-47-D cell line. As mentioned above, this could be explained by the release of low-molecular-mass oligosaccharides from cell-associated hyaluronic acid after hyaluronidase cleavage.
Although hyaluronidase itself was ineffective in vitro, we decided to investigate the effect of high-dose hyaluronidase therapy on the MXT M3.2 mammary carcinoma in vivo, since often there ist a discrepancy between the large amount of hyaluronic acid found in solid tumours, and the only small amounts of polysaccharide produced in cell culture. Coculture experiments of tumour cells with fibroblasts indicate that the tumour cells stimulate the synthesis of hyaluronic acid by fibroblasts (Knudson et al. 1984b ) via a membrane-bound (Knudson and Toole 1988) or a secreted stimulatory factor (Larnier et al. 1989; Decker et al. 1989) . Thus, interactions between tumour cells and fibroblasts of the host seem to be responsible for the high hyaluronate concentration found in tumours. Forrester and Wilkinson (1981) reported that concentrated solutions of hyaluronan inhibited the migration of certain types of leukocytes, particularly neutrophils. Inhibition of leukocyte locomotion in combination with the formation of hyaluronidase-labile coats ("halos") around cancer cells, induced in mixed culture with peripheral blood mononuclear cells (Z/inker et al. 1982; Gately et al. 1984) , might confer "immunoprotection" on the tumour in vivo. In addition, hyaluronate has been demonstrated to be unique among the glycosaminoglycans in that it can stimulate or inhibit angiogenesis directly, depending on its size. Whereas hyaluronate-rich stroma inhibits blood vessel formation, low-molecularmass oligosaccharides, as formed by hyaluronidase hydrolysis, stimulate angiogenesis in chick embryos (West and Kumar 1989) .
Unfortunately, there was no evidence for the implication of the discussed mechanisms above in the proliferation of the MXT M3.2 mammary tumour of the B6D2F 1 mouse. As shown in Fig. 1 , high-dose peritumoural hyaluronidase treatment failed to inhibit tumour growth. However, this experiment proved that hyaluronidase is excellently tolerated, even when administered at "megadoses". Our findings are consistent with the "noeffect level" of hyaluronidase in mice being 1.5 x 106 IU/ kg for a single i.v. injection (Baumgartner and Moritz 1988) .
Some clinical observations suggest that hyaluronidase preinfusion potentiates the effectiveness of chemotherapy (Baumgartner 1987 (Baumgartner , 1988 Baumgartner and Moritz 1988) . The results of our experiments, comparing the antitumour activity of Adriamycin itself with the activity of a combination of Adriamycin and hyaluronidase against breat cancer in vitro and in vivo, support the clinical data. Figure 2 shows that the cytotoxic effect of Adriamycin against the MXT + celt line was enhanced in the presence of hyaluronidase. The augmentation of Adriamycin cytotoxicity is consistent with the data re-ported by Lehnert et al. (1989) who could show, in the clonogenic assay, that the activity of doxorubicin on the murine P 388 leukemia cell line was enhanced in the presence of hyaluronidase.
The enhancement of Adriamycin activity in combination with hyaluronidase was even more impressive in vivo (cf. Fig. 3 ). The most straightforward mechanism to explain this quantitative difference is the enzymatic degradation of the hyaluronate-enriched intercellular matrix in solid tumours. By generating hydrated intercellular space, hyaluronidase facilitates diffusion of Adriamycin. As a consequence, tumour growth is inhibited indirectly, by the improved availability of the chemotherapeutic.
In this study we could demonstrate that hyaluronidase, when administered at high doses, can principally potentiate the activity of Adriamycin against experimental breast cancer, without increasing toxic side-effects. Further work must prove whether potentiation of antineoplastic activity will still be maintained after the systemic administration of lower doses of hyaluronidase. Nevertheless, if the results of these future studies were to be negative, high-dose hyaluronidase, in combination with chemotherapeutics, may still lead to an improvement of the outcome of isolated limb perfusion, practiced in the therapy of malignant melanoma.
